GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » ROA %

Accolade (Accolade) ROA % : -3.82% (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Accolade ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Accolade's annualized Net Income for the quarter that ended in Feb. 2024 was $-30.0 Mil. Accolade's average Total Assets over the quarter that ended in Feb. 2024 was $786.8 Mil. Therefore, Accolade's annualized ROA % for the quarter that ended in Feb. 2024 was -3.82%.

The historical rank and industry rank for Accolade's ROA % or its related term are showing as below:

ACCD' s ROA % Range Over the Past 10 Years
Min: -130.17   Med: -42   Max: -11.8
Current: -11.86

During the past 7 years, Accolade's highest ROA % was -11.80%. The lowest was -130.17%. And the median was -42.00%.

ACCD's ROA % is ranked worse than
74.59% of 669 companies
in the Healthcare Providers & Services industry
Industry Median: 1.28 vs ACCD: -11.86

Accolade ROA % Historical Data

The historical data trend for Accolade's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade ROA % Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
ROA %
Get a 7-Day Free Trial -73.90 -18.46 -13.98 -42.00 -11.80

Accolade Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.40 -17.27 -15.18 -10.28 -3.82

Competitive Comparison of Accolade's ROA %

For the Health Information Services subindustry, Accolade's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's ROA % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's ROA % distribution charts can be found below:

* The bar in red indicates where Accolade's ROA % falls into.



Accolade ROA % Calculation

Accolade's annualized ROA % for the fiscal year that ended in Feb. 2024 is calculated as:

ROA %=Net Income (A: Feb. 2024 )/( (Total Assets (A: Feb. 2023 )+Total Assets (A: Feb. 2024 ))/ count )
=-99.805/( (903.069+788.151)/ 2 )
=-99.805/845.61
=-11.80 %

Accolade's annualized ROA % for the quarter that ended in Feb. 2024 is calculated as:

ROA %=Net Income (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=-30.028/( (785.471+788.151)/ 2 )
=-30.028/786.811
=-3.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Feb. 2024) net income data. ROA % is displayed in the 30-year financial page.


Accolade  (NAS:ACCD) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=-30.028/786.811
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-30.028 / 499.324)*(499.324 / 786.811)
=Net Margin %*Asset Turnover
=-6.01 %*0.6346
=-3.82 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Accolade ROA % Related Terms

Thank you for viewing the detailed overview of Accolade's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111

Accolade (Accolade) Headlines

From GuruFocus

Accolade Inc CFO Stephen Barnes Sells 640 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Accolade Announces Upcoming Investor Events

By sperokesalga sperokesalga 05-08-2023

Accolade To Present at Stifel 2023 Cross Sector Insight Conference

By sperokesalga sperokesalga 06-01-2023

Accolade to Announce Fiscal First Quarter 2024 Financial Results

By sperokesalga sperokesalga 06-13-2023

Accolade Inc CEO Rajeev Singh Sells 1,456 Shares

By GuruFocus Research 05-27-2023

Report: Employees are Overwhelmed, Delaying Care at High Rates

By PRNewswire PRNewswire 06-05-2023